ERBB2 and breast carcinoma: To investigate whether GSK-J4 can mitigate trastuzumab resistance in HER2-positive breast cancer cells in vivo, we established xenograft mouse models by transplanting JIMT1 cells into the lower flanks of BALB/c nude mice and treating them with trastuzumab and/or GSK-J4 (Figure 6a).